|Bid||176.70 x 1000|
|Ask||176.61 x 1200|
|Day's Range||174.07 - 177.15|
|52 Week Range||155.72 - 186.69|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||26.45|
|Earnings Date||Apr 18, 2022 - Apr 22, 2022|
|Forward Dividend & Yield||4.52 (2.56%)|
|Ex-Dividend Date||May 23, 2022|
|1y Target Est||191.42|
Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) com
We discuss areas that could outperform in the current market environment.
Companies could be returning trillions to shareholders. Here’s how to accept it.